On Monday’s call, Hims & Hers CFO Oluyemi Okupe said that personalized semaglutide dosages will supplement the company’s core offerings. The company announced in November that it plans to ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is still a buy.

Executives of Hims & Hers always knew their ability to sell ... the FDA’s drug-shortage database indicated that all dosages of semaglutide were available, a precursor to resolving the shortage.

Novo Nordisk and a popular virtual health company are making Wegovy more accessible to millions of more Americans. Hims & ...

With the partnerships, Novo appears to have struck a truce with Hims & Hers after the two sparred over the telehealth company's practice of selling compounded versions of semaglutide, the active ...

Novo Nordisk's Wegovy now available via Hims & Hers at $599/month, covering all dose strengths with 24/ ... service to improve access to Wegovy (semaglutide) for cash-paying patients.

Starting this week, they’re offering a bundle of all dose strengths of the semaglutide shot and a membership to Hims & Hers for $599 a month. The partnership is aimed at making the pricey drugs ...